- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04407221
COVID-19 Research in Organ Transplant Recipients (CORONA)
COVID-19 is a global major public health emergency that disproportionately affects patients with risk factors such as advanced age, heart and lung disease, diabetes, hypertension, as well as compromised immunity. Despite the recent worldwide emergence of this disease and its rapid progression to a pandemic, very little is known about the risks facing solid organ recipients. The study aims to elucidate the prevalence of symptomatic, subclinical, and asymptomatic infection in the transplanted population by assessing their immunological response to SARS-CoV-2 infection. This will be studied seroepidemiologically in the whole cohort and retrospectively in transplanted patients admitted to hospital for COVID-19.
Primary objective: to elucidate the cumulative prevalence of SARS-CoV-2 infection in the transplanted population related to symptoms and hospitalizations; to assess the magnitude of immunological response and seroconversion kinetics for COVID-19. Secondary objectives: To examine the influence of medical parameters on COVID-19 infection and immune response such as: age, comorbidities current and recent pharmacological treatment, organ transplanted, and blood type, HLA genotype.
Study design:
Part 1: Longitudinal cohort study for seroepidemiology and disease burden. Part 2: Retrospective case-series for seroconversion kinetics and clinical course assessment.
Study population:
All solid organ transplanted patients in Sweden
Descripción general del estudio
Estado
Condiciones
Descripción detallada
The study will assess the clinical course, the outcome, and the immunologic response of organ transplant patients who have had COVID-19 (participants); The investigators aim to study the development of the immune response to COVID-19 infection to see if participants on immunosuppressive treatment, will establish sufficient immunity to protect against reinfection. The findings among participants will be compared to a suitable control population. In addition, the investigators will identify patients in our cohort who are undergoing clinically apparent infections and study their clinical course and antibody response profile in the acute phase (seroconversion).
Control groups: Other current studies with matched protocols and WHO pooled data.
Overall study design Part 1: Potential participants are all patients who have undergone solid organ transplantation (SOT) in Sweden will be invited to participate in the longitudinal cohort seroprevalence part of the study (approximately 1000 patients will be included). This part of the study is a single-center longitudinal cohort study that will evaluate the development of antibodies against SARS-CoV-2 in solid organ recipients at all stages after transplantation and study their disease course, complications, and death rate.
The study has been designed to follow the best practices outlined by the WHO in their recent guidelines entitled "Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection COVID-19 v1.1". This will allow a comparison of symptoms, outcomes, case fatality rate, as well as antibody titers and prevalence, with other relevant control groups. Participant enrollment will be allowed for a maximum of 2 years. The duration of the study will be two years from enrollment. The last participant will thus complete follow-up a maximum of 4 years after the commencement of the study Part 2: The investigators will also do a retrospective assessment of transplanted patients in Sweden with PCR confirmed COVID-19.
Tipo de estudio
Inscripción (Anticipado)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Vastra Gotaland
-
Gothenburg, Vastra Gotaland, Suecia, 41345
- The Transplant Institute
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- A patient who has undergone solid organ transplantation in Sweden
- Must be able to take part in data reporting activities, sign the consent form, and submit blood samples at predefined intervals.
Exclusion Criteria:
-Patients under 18 years of age.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test)
Periodo de tiempo: 0 months
|
Cumulative presence of SARS-CoV-2 antibodies in plasma.
|
0 months
|
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test)
Periodo de tiempo: 3 months
|
Cumulative presence of SARS-CoV-2 antibodies in plasma.
|
3 months
|
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test)
Periodo de tiempo: 6 months
|
Cumulative presence of SARS-CoV-2 antibodies in plasma.
|
6 months
|
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test)
Periodo de tiempo: 9 months
|
Cumulative presence of SARS-CoV-2 antibodies in plasma.
|
9 months
|
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test)
Periodo de tiempo: 12 months
|
Cumulative presence of SARS-CoV-2 antibodies in plasma.
|
12 months
|
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test)
Periodo de tiempo: 15 months
|
Cumulative presence of SARS-CoV-2 antibodies in plasma.
|
15 months
|
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test)
Periodo de tiempo: 18 months
|
Cumulative presence of SARS-CoV-2 antibodies in plasma.
|
18 months
|
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test)
Periodo de tiempo: 21 months
|
Cumulative presence of SARS-CoV-2 antibodies in plasma.
|
21 months
|
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test)
Periodo de tiempo: 24 months
|
Cumulative presence of SARS-CoV-2 antibodies in plasma.
|
24 months
|
Change in levels of SARS-Cov-2 antibodies (antibody titers)
Periodo de tiempo: 0-24 months
|
Change in titers of SARS-CoV-2 antibodies in plasma over time.
|
0-24 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Cellular response to SARS-Cov-2 (Th4 and Th8 levels)
Periodo de tiempo: 3 months
|
PBMC specific responses, measured in PCR/serology positive patients.
|
3 months
|
Cellular response to SARS-Cov-2 (Th4 and Th8 levels)
Periodo de tiempo: 12 months
|
PBMC specific responses, measured in PCR/serology positive patients.
|
12 months
|
Cellular response to SARS-Cov-2 (Th4 and Th8 levels)
Periodo de tiempo: 24 months
|
PBMC specific responses, measured in PCR/serology positive patients.
|
24 months
|
Change in cellular response to SARS-Cov-2 (Th4 and Th8 levels)
Periodo de tiempo: 0-24 months
|
Change in PBMC specific responses over time
|
0-24 months
|
Symptoms and hospitalisations (electronic questionnaire)
Periodo de tiempo: 0 months
|
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months.
|
0 months
|
Symptoms and hospitalisations (electronic questionnaire)
Periodo de tiempo: 3 months
|
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months.
|
3 months
|
Symptoms and hospitalisations (electronic questionnaire)
Periodo de tiempo: 6 months
|
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months.
|
6 months
|
Symptoms and hospitalisations (electronic questionnaire)
Periodo de tiempo: 9 months
|
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months.
|
9 months
|
Symptoms and hospitalisations (electronic questionnaire)
Periodo de tiempo: 12 months
|
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months.
|
12 months
|
Symptoms and hospitalisations (electronic questionnaire)
Periodo de tiempo: 15 months
|
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months.
|
15 months
|
Symptoms and hospitalisations (electronic questionnaire)
Periodo de tiempo: 18 months
|
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months.
|
18 months
|
Symptoms and hospitalisations (electronic questionnaire)
Periodo de tiempo: 21 months
|
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months.
|
21 months
|
Symptoms and hospitalisations (electronic questionnaire)
Periodo de tiempo: 24 months
|
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months.
|
24 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Mihai Oltean, MD, PhD, Transplant Institute, Sahlgrenska University
- Investigador principal: John M Søfteland, MD, PhD, Transplant Institute, Sahlgrenska University
- Director de estudio: Vanda Friman, MD, PhD, Department of Infectious diseases, Gothenburg University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- COV-19-SU-TX
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .